Printer Friendly


Sutent is used by patients with kidney and gut cancer, conditions which cannot be treated with chemotherapy or radiotherapy.

Kidney cancer charities say it is a proven licensed drug around the world. It was first made available in Britain 18 months ago.

Kidney cancer affects 6,600 UK patients a year, and 1,000 suffer from gastrointestinal stromal tumours, which Sutent also benefits.

As we reported two weeks ago, Coventry and Warwickshire PCTs say it would not be costeffective to routinely prescribe Sutent given the evidence of its benefits, tight budgets and the needs of other patients.

To back the campaign, sign a e-petition on the 10, Downing Street website at /kidneycancerRCC/

For more information, go to the Kidney Cancer UK website
COPYRIGHT 2008 Coventry Newpapers
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Coventry Evening Telegraph (England)
Date:Feb 8, 2008
Previous Article:If it wasn't for drug, I don't think I'd be here; CANCER: Patient who won battle to get treatment on NHS is now fighting for others.
Next Article:We can't afford to pay.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters